Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBI-02
- Development stage
- Unknown
- Lead developer
- Therabest
- Modality
- Adoptive Cell Transfer → Cell Therapies
- Administration
- Parenteral
01
Overview
EBI-02 is an ex vivo boosted immune cell-human (EBI-H) cell therapy developed by Therabest Korea for the treatment of liver cirrhosis. It utilizes the company’s proprietary EBI-H platform and is classified as a cell therapy with a mechanism of action described as "cell replacements." The product is currently in Phase 1 clinical development for liver cirrhosis. There are no orphan drug designations or approvals reported, and it has not been identified as a new molecular entity.
Beyond the preview
Go deeper on EBI-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBI-02.